Timothy Moran, MD, PhD, Associate Professor of Pediatrics and Mike Kulis, PhD, Professor of Pediatrics, in the Division of Allergy/Immunology were one of five team to be awarded pilot funding in support of cutting-edge New Approach Methodologies research. The team received $40,000 from the SOM Office of Research Emerging Challenges in Biomedical Research (ECBR) in support of their pilot project “Development of a human lymphoid organoid model to study food allergy immunotherapy.”
The project is a collaboration with Scott Randell, PhD (Cell Biology & Physiology), Phillip Clapp, PhD (Cell Biology & Physiology), Adam Kimple, MD, PhD (Otolaryngology), will develop human lymphoid organoids to study food allergy immunotherapy. Their proposal, Development of a Human Lymphoid Organoid Model to Study Food Allergy Immunotherapy, aims to identify Th1-promoting adjuvants that enhance the efficacy of sublingual immunotherapy for peanut allergy.
The School of Medicine Office of Research sponsors an annual pilot program, Emerging Challenges in Biomedical Research (ECBR), that provides support for innovative, early-stage research relevant to external strategic priorities. The fall 2025 round of funding was focused on advancing translational biomedical research through the use or development of New Approach Methodologies/Non-Animal Models (NAMs) and New Approach Technologies (NATs). Previous ECBR rounds have provided pilot support for Basic Science, Health Equity Research, COVID-19, Zika, Alzheimer’s Disease, Precision Healthcare and Vaping research.
Read more about the ECBR program and the other four teams/projects to be awarded funding this year.
Please join us in congratulating these teams on this significant achievement!